Patent US4923871A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4923871A Expired / Lapsed US ⏱️ 0.0 years remaining

Certain 2,6-dimethyl-4-(pyrazolo[1,5a]-pyridin-3-yl)1,4-dihydro-pyridine-3,5-dicarboxylate derivatives and compositions containing same

Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH 1-37-1 KAMIIKEBUKRO TOSHIMA-KU TOKYO JAPAN A CORP OF JAPAN
•
Filing: 1987-11-25
•
Granted: 1990-05-08
•
Expires: 2007-11-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This invention relates to new and useful 2,6-dimethyl-4-(pyrazolo[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-d icarboxylate derivatives of the following formula: <IMAGE> and pharmaceutically acceptable salts thereof, having potent promoting activity of some antitumor agents against various kinds of tumor cells including multiple drug resistant tumor cells.

Inventors

  • 👤 Makoto Inaba
  • 👤 Hirotaka Shinoda
  • 👤 Fujio Iinuma

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 16:11
CPC Classifications
C; C07; C07D; C07D471/00; C07D471/02; C07D471/04; A; A61; A61P; A61P35/00

Claims Analysis

Total Claims: 4
Claim 1
Independent Claim 35 words
A compound selected from the group consisting of dimethyl 2,6-dimethyl-4-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; methyl ethyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; butyl methyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; tert-butyl methyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; methyl octyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; N-benzyl-N-methyl-2-aminoethyl methyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; methyl 2-dimethylaminoethyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; methyl 2-(4-methyl-1-piperazinyl)ethyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; and methyl 2-(N-benzyl-N-methylamino)ethyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate.
Claim 2
Dependent Claim 35 words
A compound selected from the group consisting of dimethyl 2,6-dimethyl-4-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; methyl ethyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; butyl methyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; tert-butyl methyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; methyl octyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; N-benzyl-N-methyl-2-aminoethyl methyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; methyl 2-dimethylaminoethyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; methyl 2-(4-methyl-1-piperazinyl)ethyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; and methyl 2-(N-benzyl-N-methylamino)ethyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate.
Claim 3
Dependent Claim 21 words
A pharmaceutical composition comprising an antitumor activity promoting effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
Claim 4
Dependent Claim 41 words
The composition of claim 1 wherein the compound is selected from the group consisting of dimethyl 2,6-dimethyl-4-(2-isopropylpyrazolo[1,5-a]-pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; methyl ethyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; butyl methyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; tert-butyl methyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; methyl octyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; N-benzyl-N-methyl-2-aminoethyl methyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; methyl 2-dimethylaminoethyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3yl)-1,4-dihydropyridine-3,5-dicarboxylate; methyl 2-(4-methyl-1-piperazinyl)ethyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; methyl 2-(N-benzyl-N-methylamino)ethyl 2,6-dimethyl-4-(2-isopropylpyrazolo-[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate.

References Cited (Backward Citations)

US4808603A Cited
US4794187A Cited
US4808622A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1993-05-07 1993-11-06 1994-05-08 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1997-05-07 1997-11-06 1998-05-08 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2001-05-07 2001-11-06 2002-05-08 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag